Historical record - last NADAC effective date: 8/21/2024
Product Information
AVALIDE 300-12.5 MG TABLET is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $9.7125 per EA under NDC 00024585630. Its NADAC has been published 247 times since Nov 28, 2013.
FDA first approved this application on Sep 30, 1997. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the irbesartan and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
12.5; 300 mg/1; mg/1
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00024585630
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/21/2024
Active Ingredients
HYDROCHLOROTHIAZIDE; IRBESARTANApproval Type
New Drug (NDA)
FDA Application
NDA020758FDA Approved
9/30/1997
TE Code
AB
On Market Since
1/1/2013
Pharmacological Classes
Price Statistics
The NADAC for AVALIDE 300-12.5 MG TABLET has been published 247 times since Nov 28, 2013, and over the history we have for it it has risen 114.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.7125 per EA |
|---|---|
| All-time high | $9.7125 (Aug 13, 2025) |
| All-time low | $4.4750 (Jan 22, 2014) |
| Median price | $6.6029 |
| Average price | $7.0718 |
| Largest weekly change | +33.2% (Apr 17, 2024) |
| Weeks tracked | 247 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+33.7%
5Y
+33.7%
All
+114.1%
Last surveyed Aug 13, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the irbesartan and hydrochlorothiazide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of AVALIDE 300-12.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for AVALIDE 300-12.5 MG TABLET, manufactured by Sanofi-Aventis U.S. LLC, is $9.7125 per EA (NDC 00024585630), effective Aug 13, 2025.
How has the price of AVALIDE 300-12.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for AVALIDE 300-12.5 MG TABLET has risen 114.1%. It has been tracked across 247 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for AVALIDE 300-12.5 MG TABLET?
Since Nov 28, 2013, the NADAC for AVALIDE 300-12.5 MG TABLET has ranged from a low of $4.4750 (Jan 22, 2014) to a high of $9.7125 (Aug 13, 2025), with a median of $6.6029 per EA.
Are there cheaper alternatives to AVALIDE 300-12.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of AVALIDE 300-12.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AVALIDE 300-12.5 MG TABLET?
AVALIDE 300-12.5 MG TABLET (NDC 00024585630) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a brand product.